Quantitative Analysis of Minimal Residual Disease (MRD) Shows High Rates of Undetectable MRD after Fixed-Duration Chemotherapy-Free Treatment and Serves As Surrogate Marker for Progression-Free Survival: A Prospective Analysis of the Randomized CLL14 Trial

K Fischer; M Ritgen; O Al-Sawaf; S Robrecht; M Tandon; A M Fink; A Schilhabel; T Stübig; M Brüggemann; Y Jiang; W Schary; BF Eichhorst; CM Wendtner; E Tausch; KA Kreuzer; Ton Langerak; V Goede; S Böttcher; S Stilgenbauer; M Kneba; M Hallek

doi:10.1182/blood-2019-125825

Quantitative Analysis of Minimal Residual Disease (MRD) Shows High Rates of Undetectable MRD after Fixed-Duration Chemotherapy-Free Treatment and Serves As Surrogate Marker for Progression-Free Survival: A Prospective Analysis of the Randomized CLL14 Trial

K Fischer, M Ritgen, O Al-Sawaf, S Robrecht, M Tandon, A M Fink, A Schilhabel, T Stübig, M Brüggemann, Y Jiang, W Schary, BF Eichhorst, CM Wendtner, E Tausch, KA Kreuzer, Ton Langerak, V Goede, S Böttcher, S Stilgenbauer, M KnebaM Hallek

Immunology

Research output: Contribution to journal › Article › Academic › peer-review

Original language	Undefined/Unknown
Pages (from-to)	36
Journal	Blood
Volume	134
Issue number	1
DOIs	https://doi.org/10.1182/blood-2019-125825
Publication status	Published - 2019

Research programs

EMC OR-01

Access to Document

10.1182/blood-2019-125825

Cite this

Fischer, K., Ritgen, M., Al-Sawaf, O., Robrecht, S., Tandon, M., Fink, A. M., Schilhabel, A., Stübig, T., Brüggemann, M., Jiang, Y., Schary, W., Eichhorst, BF., Wendtner, CM., Tausch, E., Kreuzer, KA., Langerak, T., Goede, V., Böttcher, S., Stilgenbauer, S., ... Hallek, M. (2019). Quantitative Analysis of Minimal Residual Disease (MRD) Shows High Rates of Undetectable MRD after Fixed-Duration Chemotherapy-Free Treatment and Serves As Surrogate Marker for Progression-Free Survival: A Prospective Analysis of the Randomized CLL14 Trial. Blood, 134(1), 36. https://doi.org/10.1182/blood-2019-125825

@article{f0afadcfb76f4a398a28a29fde399e18,

title = "Quantitative Analysis of Minimal Residual Disease (MRD) Shows High Rates of Undetectable MRD after Fixed-Duration Chemotherapy-Free Treatment and Serves As Surrogate Marker for Progression-Free Survival: A Prospective Analysis of the Randomized CLL14 Trial",

author = "K Fischer and M Ritgen and O Al-Sawaf and S Robrecht and M Tandon and Fink, {A M} and A Schilhabel and T St{\"u}big and M Br{\"u}ggemann and Y Jiang and W Schary and BF Eichhorst and CM Wendtner and E Tausch and KA Kreuzer and Ton Langerak and V Goede and S B{\"o}ttcher and S Stilgenbauer and M Kneba and M Hallek",

year = "2019",

doi = "10.1182/blood-2019-125825",

language = "Undefined/Unknown",

volume = "134",

pages = "36",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "1",

}

Fischer, K, Ritgen, M, Al-Sawaf, O, Robrecht, S, Tandon, M, Fink, AM, Schilhabel, A, Stübig, T, Brüggemann, M, Jiang, Y, Schary, W, Eichhorst, BF, Wendtner, CM, Tausch, E, Kreuzer, KA, Langerak, T, Goede, V, Böttcher, S, Stilgenbauer, S, Kneba, M & Hallek, M 2019, 'Quantitative Analysis of Minimal Residual Disease (MRD) Shows High Rates of Undetectable MRD after Fixed-Duration Chemotherapy-Free Treatment and Serves As Surrogate Marker for Progression-Free Survival: A Prospective Analysis of the Randomized CLL14 Trial', Blood, vol. 134, no. 1, pp. 36. https://doi.org/10.1182/blood-2019-125825

Quantitative Analysis of Minimal Residual Disease (MRD) Shows High Rates of Undetectable MRD after Fixed-Duration Chemotherapy-Free Treatment and Serves As Surrogate Marker for Progression-Free Survival: A Prospective Analysis of the Randomized CLL14 Trial. / Fischer, K; Ritgen, M; Al-Sawaf, O et al.
In: Blood, Vol. 134, No. 1, 2019, p. 36.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Quantitative Analysis of Minimal Residual Disease (MRD) Shows High Rates of Undetectable MRD after Fixed-Duration Chemotherapy-Free Treatment and Serves As Surrogate Marker for Progression-Free Survival: A Prospective Analysis of the Randomized CLL14 Trial

AU - Fischer, K

AU - Ritgen, M

AU - Al-Sawaf, O

AU - Robrecht, S

AU - Tandon, M

AU - Fink, A M

AU - Schilhabel, A

AU - Stübig, T

AU - Brüggemann, M

AU - Jiang, Y

AU - Schary, W

AU - Eichhorst, BF

AU - Wendtner, CM

AU - Tausch, E

AU - Kreuzer, KA

AU - Langerak, Ton

AU - Goede, V

AU - Böttcher, S

AU - Stilgenbauer, S

AU - Kneba, M

AU - Hallek, M

PY - 2019

Y1 - 2019

U2 - 10.1182/blood-2019-125825

DO - 10.1182/blood-2019-125825

M3 - Article

SN - 0006-4971

VL - 134

SP - 36

JO - Blood

JF - Blood

IS - 1

ER -

Fischer K, Ritgen M, Al-Sawaf O, Robrecht S, Tandon M, Fink AM et al. Quantitative Analysis of Minimal Residual Disease (MRD) Shows High Rates of Undetectable MRD after Fixed-Duration Chemotherapy-Free Treatment and Serves As Surrogate Marker for Progression-Free Survival: A Prospective Analysis of the Randomized CLL14 Trial. Blood. 2019;134(1):36. doi: 10.1182/blood-2019-125825